west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "杨琴" 8 results
  • Clinical Biological Characters of Acute Leukemia with Cross-lineage Expression

    【摘要】 目的 分析交叉抗原表达的急性白血病的临床特征及缓解率。 方法 对2009年10月-2010年11月血液内科的210例交叉表达髓系和淋巴细胞系相关抗原的初治急性白血病患者的标本,采用流式细胞术检测白血病细胞的免疫表型,根据免疫标记和FAB(French、American、Britain)分型进行分组,分析其异质性的生物学特征和影响缓解率的相关因素。 结果 210例急性白血病的FAB分型以AML-M1/M2(82例)和ALL(78例)为主;免疫分型以B淋巴细胞系和髓系混合表达多见(116例),其中CD34表达率高达91.4%(192例), CD7表达率为50.5%(106例),且与CD34相关(P=0.04);出现CD34、CD7、CD19三者共表达的患者缓解率较低(9.09%)。 结论 交叉抗原表达的急性白血病的诊断有赖于免疫分型的判断,其分化抗原的表达类型是影响其缓解率的重要因素。【Abstract】 Objective To observe the clinical characters of acute leukemia with cross-lineage antigen expression and analyze the remission rate. Methods Between October 2009 and November 2010, 210 patients were diagnosed and classified by morphology. Cytochemistry and immunology were used to analyze the immunophenotype. According to the immunostaining relative factors and FAB (French, American, and Britain) phenotype standard, the samples were divided into several groups. The conical characters and relative factors of remission rate were analyzed. Results In 210 patients with cross-lineage antigen expression, AL, AML-M1/M2 (82 cases) and ALL (78 cases) were common in FAB phenotype,and cross-lineage of B lineage and myelolineage were common in immunotype (116 cases). CD34 got the highest expression frequency of all (192 cases),and had the most important effect on patients′ prognosis. CD7 was also positive commonly (106 cases) and related with CD34 (P=0.04). So it′s significant for the outcome. The patients who got co-expression of CD34, CD7 and CD19 had worse prognoses. Conclusions Acute leukemia with cross-lineage antigen expression is a special type and is confirmed by immunotype. Furthermore, expression types of differentiation antigen are critical for the prognosis.

    Release date:2016-09-08 09:27 Export PDF Favorites Scan
  • A preliminary study on metabonomics of amino acid and glucose in patients with gallbladder stones based on nuclear magnetic resonance

    Objective The method of metabonomics based on nuclear magnetic resonance (NMR) imaging was used to explore the difference in metabolites of serum and bile, and to analyze the metabolic variation related to the pathogenesis of gallbladder stones between normal people/liver transplantation donors and patients with gallbladder stones. Methods Prospectively collected the serum samples (17 cases) and bile samples (19 cases) in 19 patients with gallbladder stones who underwent surgery in West China Hospital form March 2016 to December 2016, as well as the serum samples of 10 healthy persons and the bile samples of 15 liver transplantation donors at the same time period. The differences of metabolites in the blood and bile in these 3 groups were compared by using 1H-NMR metabonomics technology and chemometric methods. Results The concentrations of valine, alanine, lysine, glutamine, glutamate, pyruvate, creatinine, choline, alpha-glucose, beta-glucose, tyrosine, histidine, and hypoxanthine in serum of patients with gallbladder stones decreased significantly, comparing with those of healthy people without gallbladder stones (P<0.05), while 1, 2-propanediol, acetoacetate, and lactate increased significantly in the serum of patients with gallbladder stones (P<0.05). The concentrations of taurine conjugated bile acids, glycine conjugated bile acids, choline, and phosphatidylcholine decreased significantly in the bile of patients with gallbladder stones when compared with those of liver transplantation donors (P<0.05), while cholesterol increased significantly in the bile of patients with gallbladder stones (P<0.05). Conclusions There are significant differences of the serum and bile metabolites between patients with gallbladder stones and healthy men without gallbladder stones/liver transplantation donors. 1H-NMR metabonomics is helpful to investigate the pathogenesis of gallbladder stones.

    Release date:2018-04-11 02:55 Export PDF Favorites Scan
  • Research progress of portal vein thrombosis after splenectomy

    ObjectiveTo summarize the pathogenesis, epidemiology, and risk factors of portal vein thrombosis after splenectomy, and combined with the latest advances in clinical prevention, diagnosis, and treatment of portal vein thrombosis after splenectomy, so as to provide some references for clinical prevention and treatment in the future.MethodLiteratures on portal vein thrombosis after splenectomy were collected and reviewed.ResultsThe incidence of portal vein thrombosis after splenectomy was high and its occurrence was the result of multiple factors. It was mainly related to the change of splenic venous blood flow mechanics after splenectomy. In terms of diagnosis, enhanced CT scan was the first choice. Currently, there was no consensus on treatment options, which mainly focused on individualized treatment and emphasized that preventive anticoagulant use of low-molecular-weight heparin may reduce the risk of portal vein thrombosis.ConclusionThe concept of tertiary prevention of portal vein thrombosis after splenectomy should be established, and individualized treatment should be adopted in combination with the patient’s condition.

    Release date:2020-12-25 06:09 Export PDF Favorites Scan
  • 白蛋白结合型紫杉醇致双眼黄斑水肿1例

    Release date: Export PDF Favorites Scan
  • Application progress of pre-rehabilitation in patients undergoing transcatheter aortic valve replacement

    Pre-rehabilitation is an emerging preoperative management strategy designed to mitigate surgical stress responses and expedite postoperative recovery through optimized interventions, which typically includes exercise training, nutritional support, and psychological counseling. For patients undergoing transcatheter aortic valve replacement (TAVR), the implementation of pre-rehabilitation measures is particularly crucial. This article reviews the necessity and principal components of pre-rehabilitation in TAVR patients, and offers suggestions including constructing the best pre-rehabilitation intervention program for TAVR, enhancing patient compliance and engagement in the recovery process, and paying attention to the management of frailty for TAVR patients. The aim is to provide a reference for healthcare professionals seeking to further refine the pre-rehabilitation management model for TAVR patients.

    Release date: Export PDF Favorites Scan
  • Research progress on unplanned readmissions in patients with left ventricular assist devices

    The implantation of left ventricular assist device (LVAD) has significantly improved the quality of life for patients with end-stage heart failure. However, it is assiosciated with the risk of complications, with unplanned readmissions gaining increasing attention. This article reviews the overview, influencing factors, predictive models, and intervention measures for unplanned readmissions among LVAD implantation patients. The aim is to provide scientific guidance for clinical practice, assisting healthcare professionals in accurately assessing patient conditions and formulating appropriate care plans.

    Release date: Export PDF Favorites Scan
  • 8 例贝伐珠单抗致胃肠道穿孔的临床分析

    目的观察并分析接受贝伐珠单抗治疗的恶性肿瘤患者发生胃肠道穿孔的治疗方式及预后。方法回顾性分析 2013 年 1 月至 2019 年 11 月期间在四川省肿瘤医院接受贝伐珠单抗治疗后发生胃肠道穿孔的恶性肿瘤患者的临床资料,包括穿孔后的临床特征,贝伐珠单抗使用周期、单次使用剂量及累计剂量,骨髓抑制程度,感染情况,末次使用贝伐珠单抗至发生胃肠道穿孔的时间,穿孔后治疗方式、穿孔后生存时间等相关资料。结果共纳入 8 例患者的资料进行分析,分别是左半结肠癌 2 例,右半结肠癌 3 例,直肠癌、肺癌和子宫内膜癌各 1 例。8 例患者均有腹胀、腹痛症状,5 例患者出现严重腹膜炎(肌紧张、压痛、反跳痛),4 例患者出现膈下游离气体或腹腔游离气体。贝伐珠单抗中位使用次数为 2 次(1~16 次)、上下四分位数为(2,6),中位单次剂量为 0.4 g(0.3~0.4 g)、上下四分位数为(0.3,0.4),中位累计剂量为 0.8 g(0.4~4.8 g)、上下四分位数为(0.6,2.4),末次使用贝伐珠单抗至胃肠道穿孔的中位时间为 15 d(3~68 d)、上下四分位数为(4,16)。有 5 例患者接受手术治疗,穿孔至接受手术的中位时间为 34.5 h(2~72 h)、上下四分位数为(3.5,72.0);3 例患者行保守治疗。2 例患者出现 Ⅳ 度骨髓抑制,6 例患者出现感染性休克、诊断为脓毒血症; 8 例患者经手术或保守治疗后相继死亡,中位死亡时间 23 d(15~37 d)、上下四分位数为(20,25)。结论接受贝伐珠单抗治疗的患者发生胃肠道穿孔的预后差,病死率高,在治疗过程中需密切关注相关并发症风险并在起病早期及早干预。

    Release date:2021-04-30 10:45 Export PDF Favorites Scan
  • The risk prediction models for anastomotic leakage after esophagectomy: A systematic review and meta-analysis

    ObjectiveTo systematically evaluate the risk prediction models for anastomotic leakage (AL) in patients with esophageal cancer after surgery. MethodsA computer-based search of PubMed, EMbase, Web of Science, Cochrane Library, Chinese Medical Journal Full-text Database, VIP, Wanfang and CNKI was conducted to collect studies on postoperative AL risk prediction model for esophageal cancer from their inception to October 1st, 2023. PROBAST tool was employed to evaluate the bias risk and applicability of the model, and Stata 15 software was utilized for meta-analysis. ResultsA total of 19 literatures were included covering 25 AL risk prediction models and 7373 patients. The area under the receiver operating characteristic curve (AUC) was 0.67-0.960. Among them, 23 prediction models had a good prediction performance (AUC>0.7); 13 models were tested for calibration of the model; 1 model was externally validated, and 10 models were internally validated. Meta-analysis showed that hypoproteinemia (OR=9.362), postoperative pulmonary complications (OR=7.427), poor incision healing (OR=5.330), anastomosis type (OR=2.965), preoperative history of thoracoabdominal surgery (OR=3.181), preoperative diabetes mellitus (OR=2.445), preoperative cardiovascular disease (OR=3.260), preoperative neoadjuvant (OR=2.977), preoperative respiratory disease (OR=4.744), surgery method (OR=4.312), American Society of Anesthesiologists score (OR=2.424) were predictors for AL after esophageal cancer surgery. ConclusionAt present, the prediction model of AL risk in patients with esophageal cancer after surgery is in the development stage, and the overall research quality needs to be improved.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content